36 related articles for article (PubMed ID: 9456296)
1. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.
Belle DJ; Callaghan JT; Gorski JC; Maya JF; Mousa O; Wrighton SA; Hall SD
Br J Clin Pharmacol; 2002 Jan; 53(1):67-74. PubMed ID: 11849197
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1Beta- and 5Beta-hydroxylation of Deoxycholate and Glycodeoxycholate as In Vitro Index Reactions for Cytochrome P450 3A Activities.
Wang C; Cheng B; Wei W; Gui L; Zeng W; Wang Y; Wang Y; Chen Q; Xu L; Miao J; Lan K
Drug Metab Dispos; 2024 Jan; 52(2):126-134. PubMed ID: 38050044
[TBL] [Abstract][Full Text] [Related]
3. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.
Empey PE; Miller TM; Philbrick AH; Melick JA; Kochanek PM; Poloyac SM
Crit Care Med; 2012 Apr; 40(4):1221-8. PubMed ID: 22067624
[TBL] [Abstract][Full Text] [Related]
4. Danazol increases the oral bioavailability of midazolam by inactivation of hepatic and intestinal CYP3A in rats.
Fukuno S; Nagai K; Kurotobi A; Sahori Y; Nakagawa R; Nomura R; Ito T; Konishi H
Xenobiotica; 2023 May; 53(5):421-428. PubMed ID: 37640546
[TBL] [Abstract][Full Text] [Related]
5. Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.
Henderson CJ; McLaughlin LA; Osuna-Cabello M; Taylor M; Gilbert I; McLaren AW; Wolf CR
Biochem J; 2015 Feb; 465(3):479-88. PubMed ID: 25377919
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases.
Hulin A; Gelé T; Fenioux C; Kempf E; Sahali D; Tournigand C; Ollero M
Clin J Am Soc Nephrol; 2023 Dec; ():. PubMed ID: 38079278
[TBL] [Abstract][Full Text] [Related]
7. Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part I-Editorial.
Zhong XB; Lai Y; Ding X
Drug Metab Dispos; 2023 Oct; 51(10):1227-1229. PubMed ID: 37709358
[No Abstract] [Full Text] [Related]
8. UDP-Glucuronosyltransferase (UGT)-mediated attenuations of cytochrome P450 3A4 activity: UGT isoform-dependent mechanism of suppression.
Miyauchi Y; Tanaka Y; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H; Ishii Y
Br J Pharmacol; 2020 Mar; 177(5):1077-1089. PubMed ID: 31660580
[TBL] [Abstract][Full Text] [Related]
9. The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism.
Rezaee MM; Kazemi S; Kazemi MT; Gharooee S; Yazdani E; Gharooee H; Shiran MR; Moghadamnia AA
Daru; 2014 Jan; 22(1):8. PubMed ID: 24398010
[TBL] [Abstract][Full Text] [Related]
10. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
11. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
12. Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers.
Xin HW; Wu XC; Li Q; Yu AR; Xiong L
Br J Clin Pharmacol; 2009 May; 67(5):541-6. PubMed ID: 19552749
[TBL] [Abstract][Full Text] [Related]
13. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
14. A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.
Sharma A; Pilote S; Bélanger PM; Arsenault M; Hamelin BA
Br J Clin Pharmacol; 2004 Sep; 58(3):288-97. PubMed ID: 15327588
[TBL] [Abstract][Full Text] [Related]
15. The distribution and gender difference of CYP3A activity in Chinese subjects.
Zhu B; Liu ZQ; Chen GL; Chen XP; Ou-Yang DS; Wang LS; Huang SL; Tan ZR; Zhou HH
Br J Clin Pharmacol; 2003 Mar; 55(3):264-9. PubMed ID: 12630976
[TBL] [Abstract][Full Text] [Related]
16. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Andersen V; Pedersen N; Larsen NE; Sonne J; Larsen S
Br J Clin Pharmacol; 2002 Aug; 54(2):120-4. PubMed ID: 12207630
[TBL] [Abstract][Full Text] [Related]
17. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.
Wandel C; Böcker RH; Böhrer H; deVries JX; Hofmann W; Walter K; Kleingeist B; Neff S; Ding R; Walter-Sack I; Martin E
Drug Metab Dispos; 1998 Feb; 26(2):110-4. PubMed ID: 9456296
[TBL] [Abstract][Full Text] [Related]
18. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
19. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
